Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 129 entries
Sorted by: Best Match Show Resources per page
Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment.

Future oncology (London, England)

Mangano A, Lianos GD, Mangano A, Boni L, Dionigi G.
PMID: 25686113
Future Oncol. 2015;11(4):561-4. doi: 10.2217/fon.14.296.

No abstract available.

Cite
Mangano A, Lianos GD, Mangano A, et al. Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment. Future Oncol. 2015;11(4):561-4doi: 10.2217/fon.14.296.
Mangano, A., Lianos, G. D., Mangano, A., Boni, L., & Dionigi, G. (2015). Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment. Future oncology (London, England), 11(4), 561-4. https://doi.org/10.2217/fon.14.296
Mangano, Alberto, et al. "Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment." Future oncology (London, England) vol. 11,4 (2015): 561-4. doi: https://doi.org/10.2217/fon.14.296
Mangano A, Lianos GD, Mangano A, Boni L, Dionigi G. Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment. Future Oncol. 2015;11(4):561-4. doi: 10.2217/fon.14.296. PMID: 25686113.
Copy Download .nbib Format: NLM
Integrated cancer tissue engineering models for precision medicine.

PloS one

Bregenzer ME, Horst EN, Mehta P, Novak CM, Raghavan S, Snyder CS, Mehta G.
PMID: 31075118
PLoS One. 2019 May 10;14(5):e0216564. doi: 10.1371/journal.pone.0216564. eCollection 2019.

Tumors are not merely cancerous cells that undergo mindless proliferation. Rather, they are highly organized and interconnected organ systems. Tumor cells reside in complex microenvironments in which they are subjected to a variety of physical and chemical stimuli that...

Cite
Bregenzer ME, Horst EN, Mehta P, et al. Integrated cancer tissue engineering models for precision medicine. PLoS One. 2019;14(5):e0216564doi: 10.1371/journal.pone.0216564.
Bregenzer, M. E., Horst, E. N., Mehta, P., Novak, C. M., Raghavan, S., Snyder, C. S., & Mehta, G. (2019). Integrated cancer tissue engineering models for precision medicine. PloS one, 14(5), e0216564. https://doi.org/10.1371/journal.pone.0216564
Bregenzer, Michael E, et al. "Integrated cancer tissue engineering models for precision medicine." PloS one vol. 14,5 (2019): e0216564. doi: https://doi.org/10.1371/journal.pone.0216564
Bregenzer ME, Horst EN, Mehta P, Novak CM, Raghavan S, Snyder CS, Mehta G. Integrated cancer tissue engineering models for precision medicine. PLoS One. 2019 May 10;14(5):e0216564. doi: 10.1371/journal.pone.0216564. eCollection 2019. PMID: 31075118; PMCID: PMC6510431.
Copy Download .nbib Format: NLM
Metabolic pattern formation in the tumor microenvironment.

Molecular systems biology

Dai Z, Locasale JW.
PMID: 28183842
Mol Syst Biol. 2017 Feb 09;13(2):915. doi: 10.15252/msb.20167518.

No abstract available.

Cite
Dai Z, Locasale JW. Metabolic pattern formation in the tumor microenvironment. Mol Syst Biol. 2017;13(2):915doi: 10.15252/msb.20167518.
Dai, Z., & Locasale, J. W. (2017). Metabolic pattern formation in the tumor microenvironment. Molecular systems biology, 13(2), 915. https://doi.org/10.15252/msb.20167518
Dai, Ziwei, and Locasale, Jason W. "Metabolic pattern formation in the tumor microenvironment." Molecular systems biology vol. 13,2 (2017): 915. doi: https://doi.org/10.15252/msb.20167518
Dai Z, Locasale JW. Metabolic pattern formation in the tumor microenvironment. Mol Syst Biol. 2017 Feb 09;13(2):915. doi: 10.15252/msb.20167518. PMID: 28183842; PMCID: PMC5327726.
Copy Download .nbib Format: NLM
Tumor self-responsive upconversion nanomedicines for theranostic applications.

Nanoscale

Xu J, Gulzar A, Yang D, Gai S, He F, Yang P.
PMID: 31553008
Nanoscale. 2019 Oct 03;11(38):17535-17556. doi: 10.1039/c9nr06450h.

To date, malignant tumors continue to be the most lethal disease, causing more than 8.2 million deaths worldwide each year. In recent years, nanostructures based on rare-earth upconversion luminescent nanoparticles have shown significant advantages in the integration of multimodal...

Cite
Xu J, Gulzar A, Yang D, et al. Tumor self-responsive upconversion nanomedicines for theranostic applications. Nanoscale. 2019;11(38):17535-17556doi: 10.1039/c9nr06450h.
Xu, J., Gulzar, A., Yang, D., Gai, S., He, F., & Yang, P. (2019). Tumor self-responsive upconversion nanomedicines for theranostic applications. Nanoscale, 11(38), 17535-17556. https://doi.org/10.1039/c9nr06450h
Xu, Jiating, et al. "Tumor self-responsive upconversion nanomedicines for theranostic applications." Nanoscale vol. 11,38 (2019): 17535-17556. doi: https://doi.org/10.1039/c9nr06450h
Xu J, Gulzar A, Yang D, Gai S, He F, Yang P. Tumor self-responsive upconversion nanomedicines for theranostic applications. Nanoscale. 2019 Oct 03;11(38):17535-17556. doi: 10.1039/c9nr06450h. PMID: 31553008.
Copy Download .nbib Format: NLM
Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.

Clinical cancer research : an official journal of the American Association for Cancer Research

Willis JA, Overman MJ, Vilar E.
PMID: 31263028
Clin Cancer Res. 2019 Sep 01;25(17):5185-5187. doi: 10.1158/1078-0432.CCR-19-1447. Epub 2019 Jul 01.

New approaches are required for addressing the important and unmet need to expand the benefits of checkpoint blockade to patients with mismatch repair proficient colorectal cancer. Systematic profiling of the tumor immune microenvironment provides insights into potential mechanisms of...

Cite
Willis JA, Overman MJ, Vilar E. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond. Clin Cancer Res. 2019;25(17):5185-5187doi: 10.1158/1078-0432.CCR-19-1447.
Willis, J. A., Overman, M. J., & Vilar, E. (2019). Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(17), 5185-5187. https://doi.org/10.1158/1078-0432.CCR-19-1447
Willis, Jason A, et al. "Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 25,17 (2019): 5185-5187. doi: https://doi.org/10.1158/1078-0432.CCR-19-1447
Willis JA, Overman MJ, Vilar E. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond. Clin Cancer Res. 2019 Sep 01;25(17):5185-5187. doi: 10.1158/1078-0432.CCR-19-1447. Epub 2019 Jul 01. PMID: 31263028; PMCID: PMC6726523.
Copy Download .nbib Format: NLM
In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

Ozcelikkale A, Moon HR, Linnes M, Han B.
PMID: 28198106
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Sep;9(5). doi: 10.1002/wnan.1460. Epub 2017 Feb 14.

Advances in nanotechnology have enabled numerous types of nanoparticles (NPs) to improve drug delivery to tumors. While many NP systems have been proposed, their clinical translation has been less than anticipated primarily due to failure of current preclinical evaluation...

Cite
Ozcelikkale A, Moon HR, Linnes M, et al. In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(5)doi: 10.1002/wnan.1460.
Ozcelikkale, A., Moon, H. R., Linnes, M., & Han, B. (2017). In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 9(5), . https://doi.org/10.1002/wnan.1460
Ozcelikkale, Altug, et al. "In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles." Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology vol. 9,5 (2017). doi: https://doi.org/10.1002/wnan.1460
Ozcelikkale A, Moon HR, Linnes M, Han B. In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Sep;9(5). doi: 10.1002/wnan.1460. Epub 2017 Feb 14. PMID: 28198106; PMCID: PMC5555839.
Copy Download .nbib Format: NLM
[An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate].

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia

Noguera R, Burgos-Panadero R, Gamero-Sandemetrio E, de la Cruz-Merino L, Álvaro Naranjo T.
PMID: 30902384
Rev Esp Patol. 2019 Apr - Jun;52(2):92-102. doi: 10.1016/j.patol.2018.11.003. Epub 2019 Feb 10.

The group of diseases that we call cancer share a biological structure formed by a complex ecosystem, with altered intercellular communication, information fields, development and tissue function. Beyond the genetic alterations of the tumor cell, the demonstration of an...

Cite
Noguera R, Burgos-Panadero R, Gamero-Sandemetrio E, et al. Una visión integral del cáncer (I). Microambiente tumoral: estudio, clasificación y reprogramación. [An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate]. Rev Esp Patol. 2019;52(2):92-102doi: 10.1016/j.patol.2018.11.003.
Noguera, R., Burgos-Panadero, R., Gamero-Sandemetrio, E., de la Cruz-Merino, L., & Álvaro Naranjo, T. (2019). Una visión integral del cáncer (I). Microambiente tumoral: estudio, clasificación y reprogramación. [An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate]. Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia, 52(2), 92-102. https://doi.org/10.1016/j.patol.2018.11.003
Noguera, Rosa, et al. "Una visión integral del cáncer (I). Microambiente tumoral: estudio, clasificación y reprogramación." [An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate]. Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia vol. 52,2 (2019): 92-102. doi: https://doi.org/10.1016/j.patol.2018.11.003
Noguera R, Burgos-Panadero R, Gamero-Sandemetrio E, de la Cruz-Merino L, Álvaro Naranjo T. Una visión integral del cáncer (I). Microambiente tumoral: estudio, clasificación y reprogramación. [An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate]. Rev Esp Patol. 2019 Apr - Jun;52(2):92-102. doi: 10.1016/j.patol.2018.11.003. Epub 2019 Feb 10. Spanish. PMID: 30902384.
Copy Download .nbib Format: NLM
[No title available]

Cancer research

Van Dang C.
PMID: 29654150
Cancer Res. 2018 Apr 15;78(8):1889. doi: 10.1158/0008-5472.CAN-18-0711.

No abstract available.

Cite
Van Dang C. . Cancer Res. 2018;78(8):1889doi: 10.1158/0008-5472.CAN-18-0711.
Van Dang, C. (2018). . Cancer research, 78(8), 1889. https://doi.org/10.1158/0008-5472.CAN-18-0711
Van Dang, Chi. "." Cancer research vol. 78,8 (2018): 1889. doi: https://doi.org/10.1158/0008-5472.CAN-18-0711
Van Dang C. . Cancer Res. 2018 Apr 15;78(8):1889. doi: 10.1158/0008-5472.CAN-18-0711. PMID: 29654150.
Copy Download .nbib Format: NLM
Systems biology: confronting the complexity of cancer.

Cancer research

Gentles AJ, Gallahan D.
PMID: 21896642
Cancer Res. 2011 Sep 15;71(18):5961-4. doi: 10.1158/0008-5472.CAN-11-1569. Epub 2011 Sep 06.

The AACR-NCI Conference "Systems Biology: Confronting the Complexity of Cancer" took place from February 27 to March 2, 2011, in San Diego, CA. Several themes resonated during the meeting, notably (i) the need for better methods to distill insights...

Cite
Gentles AJ, Gallahan D. Systems biology: confronting the complexity of cancer. Cancer Res. 2011;71(18):5961-4doi: 10.1158/0008-5472.CAN-11-1569.
Gentles, A. J., & Gallahan, D. (2011). Systems biology: confronting the complexity of cancer. Cancer research, 71(18), 5961-4. https://doi.org/10.1158/0008-5472.CAN-11-1569
Gentles, Andrew J, and Gallahan, Daniel. "Systems biology: confronting the complexity of cancer." Cancer research vol. 71,18 (2011): 5961-4. doi: https://doi.org/10.1158/0008-5472.CAN-11-1569
Gentles AJ, Gallahan D. Systems biology: confronting the complexity of cancer. Cancer Res. 2011 Sep 15;71(18):5961-4. doi: 10.1158/0008-5472.CAN-11-1569. Epub 2011 Sep 06. PMID: 21896642; PMCID: PMC3174325.
Copy Download .nbib Format: NLM
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.

Cancer discovery

Xiao Y, Freeman GJ.
PMID: 25583798
Cancer Discov. 2015 Jan;5(1):16-8. doi: 10.1158/2159-8290.CD-14-1397.

The microsatellite instable (MSI) subset of colorectal cancer exhibits an active Th1/CTL immune microenvironment, probably due to recognition of a high number of tumor neoantigens. However, the high expression of checkpoint molecules PD-1, PD-L1, CTLA-4, LAG-3, and IDO in...

Cite
Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015;5(1):16-8doi: 10.1158/2159-8290.CD-14-1397.
Xiao, Y., & Freeman, G. J. (2015). The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer discovery, 5(1), 16-8. https://doi.org/10.1158/2159-8290.CD-14-1397
Xiao, Yanping, and Freeman, Gordon J. "The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy." Cancer discovery vol. 5,1 (2015): 16-8. doi: https://doi.org/10.1158/2159-8290.CD-14-1397
Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015 Jan;5(1):16-8. doi: 10.1158/2159-8290.CD-14-1397. PMID: 25583798; PMCID: PMC4295637.
Copy Download .nbib Format: NLM
Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?.

Clinical cancer research : an official journal of the American Association for Cancer Research

Morris JS, Kopetz S.
PMID: 27334836
Clin Cancer Res. 2016 Aug 15;22(16):3989-91. doi: 10.1158/1078-0432.CCR-16-1044. Epub 2016 Jun 22.

The tumor microenvironment contributes important information in gene expression signatures but may be susceptible to sampling variance. Mesenchymal signatures in particular may be influenced by sampling of nonrepresentative regions with high stromal content. Appropriate pathology quality control is required...

Cite
Morris JS, Kopetz S. Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?. Clin Cancer Res. 2016;22(16):3989-91doi: 10.1158/1078-0432.CCR-16-1044.
Morris, J. S., & Kopetz, S. (2016). Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(16), 3989-91. https://doi.org/10.1158/1078-0432.CCR-16-1044
Morris, Jeffrey S, and Kopetz, Scott. "Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 22,16 (2016): 3989-91. doi: https://doi.org/10.1158/1078-0432.CCR-16-1044
Morris JS, Kopetz S. Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?. Clin Cancer Res. 2016 Aug 15;22(16):3989-91. doi: 10.1158/1078-0432.CCR-16-1044. Epub 2016 Jun 22. PMID: 27334836; PMCID: PMC4987158.
Copy Download .nbib Format: NLM
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.

Frontiers in immunology

Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J.
PMID: 31440242
Front Immunol. 2019 Aug 07;10:1848. doi: 10.3389/fimmu.2019.01848. eCollection 2019.

Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune responses creating a "cold" immunosuppressive tumor microenvironment. Oncolytic virotherapy is emerging as a promising approach to revert tumor immunosuppression and enhance the efficacy of other forms of immunotherapy....

Cite
Marchini A, Daeffler L, Pozdeev VI, et al. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Front Immunol. 2019;10:1848doi: 10.3389/fimmu.2019.01848.
Marchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A., & Rommelaere, J. (2019). Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Frontiers in immunology, 101848. https://doi.org/10.3389/fimmu.2019.01848
Marchini, Antonio, et al. "Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study." Frontiers in immunology vol. 10 (2019): 1848. doi: https://doi.org/10.3389/fimmu.2019.01848
Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Front Immunol. 2019 Aug 07;10:1848. doi: 10.3389/fimmu.2019.01848. eCollection 2019. PMID: 31440242; PMCID: PMC6692828.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 129 entries